MW Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug
By Steve Goldstein
Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player.
Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases.
The candidate, currently called UBT251, is what's called a triple agonist of the receptors for GLP-1, GIP, and glucagon. In a Phase 1 trial, the highest dose group achieved an average weight loss of 15.1%, compared with 1.5% for the placebo.
Behind the Ozempic and Wegovy drugs to treat diabetes and weight loss, Novo Nordisk became Europe's top company by market cap, though it's now fallen from that perch.
Novo Nordisk shares (DK:NOVO.B) $(NVO)$ fell 3% on Monday and have dropped 18% this year, as the Danish drugmaker's trial of a key next-generation drug disappointed investors.
United Laboratories International shares (HK:3933) rallied 6% in Hong Kong trade, and have gained 35% this year.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 24, 2025 06:55 ET (10:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。